 Building the team with experienced biotech experts and renowned leaders in the ADC field  Underscores company’s commitment to progressing lead program on novel ADC target uPARAP Copenhagen, Denmark, December 1st, 2021 – Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announced today […]